GE HealthCare stock (US36266G1076): valuation metrics after recent price target moves

GE HealthCare shares trade on Nasdaq under the ticker GEHC, with investors digesting fresh valuation signals after large institutional holders updated their positions and banks fine-tuned price targets and ratings.

GE HealthCare shares, listed on Nasdaq under the ticker GEHC in the United States, remain in focus as investors weigh updated valuation metrics, institutional ownership changes, and recent shifts in Wall Street price targets for the medical technology group.

The stock most recently traded on Nasdaq in the upper USD 60s to low USD 70s range in late May 2026, according to price data from market statistics providers as of 05/27/2026, keeping GE HealthCare within a 52-week band that has stretched roughly from the high USD 50s to the high USD 80s over the past year.Investing.com as of 05/27/2026

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: GE HealthCare
• Sector/industry: Medical technology and diagnostics
• Headquarters/country: Chicago, United States
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Imaging equipment, ultrasound systems, patient monitoring and diagnostics solutions
• Home exchange/listing venue: Nasdaq (GEHC)
• Trading currency: USD

GE HealthCare: core business model

GE HealthCare focuses on advanced imaging, ultrasound, monitoring and diagnostic technologies that hospitals and healthcare providers use to deliver clinical care and run their operations efficiently, with revenue largely generated from equipment sales complemented by recurring service and software contracts.

Valuation metrics and multiples for GE HealthCare

Recent market data place GE HealthCare on earnings and cash flow multiples that reflect its profile as a large US-listed medtech group with mid-single to high-single digit revenue growth and meaningful exposure to hospital capital spending cycles.MarketBeat as of 05/28/2026 According to analyst and market screens as of late May 2026, the shares trade on a forward price-to-earnings ratio in the mid-to-high teens, based on consensus expectations for earnings over the next 12 months, which situates the company close to the broader US healthcare equipment peer group rather than at an extreme discount or premium.

Data from quarterly filings indicate that GE HealthCare reported first-quarter 2026 revenue of about USD 5.13 billion, representing year-on-year growth of roughly 7.4 percent, while delivering adjusted earnings per share of USD 0.99 for the same period, according to an earnings recap published on 05/28/2026.MarketBeat as of 04/30/2026 Taking those figures together with the current share price range implies a trailing price-to-earnings multiple somewhat above the broad-market average but in line with many large-cap diagnostic imaging peers, while enterprise-value-to-EBITDA metrics also cluster around the low-to-mid teens, reflecting the group’s cash generation and balance sheet structure.

In addition to valuation ratios, dividend policy and yield form part of the picture for shareholders assessing GE HealthCare’s equity story. As of 05/28/2026, public data show that the company has initiated a modest recurring dividend since becoming a standalone listed entity, resulting in a dividend yield in the low single digits when measured against the current share price, which keeps the stock positioned more as a growth-and-income play than as a high-yield income vehicle.MarketBeat as of 05/28/2026 On a price-to-sales basis, the current capitalization implies a multiple that reflects investor expectations for continued demand for imaging systems, ultrasound platforms and associated services, while leaving room for valuation to adjust as margins and capital allocation decisions evolve.

Conclusion

GE HealthCare’s trading range on Nasdaq and the associated valuation ratios give investors a snapshot of how the US market is currently pricing the company’s imaging, ultrasound and monitoring franchise, set against its latest reported revenue and earnings trajectory.

The valuation picture is complemented by a developing dividend profile and by shifts in institutional ownership and analyst targets, which together help shape expectations for how the stock might respond to future quarters of execution and capital allocation decisions.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.